Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
Year: 2024
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.23.02659
Authors: Philip A. Philip, Vaibhav Sahai, Nathan Bahary, Amit Mahipal, Anup Kasi, Caio Max S. Rocha Lima, Angela T. Alistar, Paul E. Oberstein, Talia Golan, Jean-Philippe Metges, Jill Lacy, Christos Fountzilas, Charles D. Lopez, Michel Ducreux, Pascal Hammel, Mohamed Salem, David Bajor, Al B. Benson, Sanjeev Luther, Timothy Pardee, Eric Van Cutsem
Institutions: Wayne State University, U-M Rogel Cancer Center, Allegheny Health Network, University Hospitals Seidman Cancer Center, Case Western Reserve University, University of Kansas Medical Center, Atrium Health Wake Forest Baptist, Wake Forest Baptist Comprehensive Cancer Center, Atlantic Health System, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Tel Aviv University, Sheba Medical Center, Yale University, Roswell Park Comprehensive Cancer Center, Oregon Health & Science University, Inserm, Institut Gustave Roussy, Université Paris-Saclay, Assistance Publique – Hôpitaux de Paris, Hôpital Paul-Brousse, Levine Cancer Institute, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, KU Leuven
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401209010